CN1989115B - 作为组胺h3受体药物的噁唑衍生物及其制备和制药用途 - Google Patents
作为组胺h3受体药物的噁唑衍生物及其制备和制药用途 Download PDFInfo
- Publication number
- CN1989115B CN1989115B CN200580024874XA CN200580024874A CN1989115B CN 1989115 B CN1989115 B CN 1989115B CN 200580024874X A CN200580024874X A CN 200580024874XA CN 200580024874 A CN200580024874 A CN 200580024874A CN 1989115 B CN1989115 B CN 1989115B
- Authority
- CN
- China
- Prior art keywords
- methyl
- ethyl
- pyrrolidin
- phenyl
- oxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *CC*1=CCCC1 Chemical compound *CC*1=CCCC1 0.000 description 4
- ZOPPZXGVEAGAGO-UHFFFAOYSA-N Brc(cc1)ccc1-c1nc(CN2CCCC2)c[o]1 Chemical compound Brc(cc1)ccc1-c1nc(CN2CCCC2)c[o]1 ZOPPZXGVEAGAGO-UHFFFAOYSA-N 0.000 description 1
- SUECTKVSIDXQQE-ZETCQYMHSA-N CC(C)(C)OC(N(CC1)C[C@H]1F)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H]1F)=O SUECTKVSIDXQQE-ZETCQYMHSA-N 0.000 description 1
- YJYKVISALZRZIS-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2-c2nc(CCN3CCCC3)c(C)[o]2)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2-c2nc(CCN3CCCC3)c(C)[o]2)OC1(C)C YJYKVISALZRZIS-UHFFFAOYSA-N 0.000 description 1
- DBBLNORBARGSIV-UHFFFAOYSA-N CC1N(Cc2c[o]c(-c(cc3)ccc3Br)n2)CCC1 Chemical compound CC1N(Cc2c[o]c(-c(cc3)ccc3Br)n2)CCC1 DBBLNORBARGSIV-UHFFFAOYSA-N 0.000 description 1
- XHUDCHGATGMDDB-UHFFFAOYSA-N CCOC(Cc1c[o]c(-c(cc2)ccc2OCc2ncccc2)n1)=O Chemical compound CCOC(Cc1c[o]c(-c(cc2)ccc2OCc2ncccc2)n1)=O XHUDCHGATGMDDB-UHFFFAOYSA-N 0.000 description 1
- JWPIUFHZDRAHKC-SECBINFHSA-N CC[C@H](CCC1)N1C(OC(C)(C)C)=O Chemical compound CC[C@H](CCC1)N1C(OC(C)(C)C)=O JWPIUFHZDRAHKC-SECBINFHSA-N 0.000 description 1
- DHIJIYYVBXUDBL-UHFFFAOYSA-N CCc(cc1)ccc1-c1nc(CN2CCCC2)c(C)[o]1 Chemical compound CCc(cc1)ccc1-c1nc(CN2CCCC2)c(C)[o]1 DHIJIYYVBXUDBL-UHFFFAOYSA-N 0.000 description 1
- SABSEDJLQPMDJT-LLVKDONJSA-N C[C@H](CCC1)N1C(Cc1c(C)[o]c(-c(cc2)ccc2O)n1)=O Chemical compound C[C@H](CCC1)N1C(Cc1c(C)[o]c(-c(cc2)ccc2O)n1)=O SABSEDJLQPMDJT-LLVKDONJSA-N 0.000 description 1
- USZQOHBPCSRMNJ-QGZVFWFLSA-N C[C@H]1N(CCc2c(C)[o]c(-c(cc3)ccc3-c3cc(C#N)ccc3)n2)CCC1 Chemical compound C[C@H]1N(CCc2c(C)[o]c(-c(cc3)ccc3-c3cc(C#N)ccc3)n2)CCC1 USZQOHBPCSRMNJ-QGZVFWFLSA-N 0.000 description 1
- DCNPTBRUXDRELW-QGZVFWFLSA-N C[C@H]1N(CCc2c(C)[o]c(-c(cc3)ccc3-c3ccccc3)n2)CCC1 Chemical compound C[C@H]1N(CCc2c(C)[o]c(-c(cc3)ccc3-c3ccccc3)n2)CCC1 DCNPTBRUXDRELW-QGZVFWFLSA-N 0.000 description 1
- WZOGAPGBVMKUKZ-OAHLLOKOSA-N C[C@H]1N(CCc2c(C)[o]c(-c(cc3)ccc3OCc3c[s]c(C)n3)n2)CCC1 Chemical compound C[C@H]1N(CCc2c(C)[o]c(-c(cc3)ccc3OCc3c[s]c(C)n3)n2)CCC1 WZOGAPGBVMKUKZ-OAHLLOKOSA-N 0.000 description 1
- ZJTLOCWXAJZYPJ-UHFFFAOYSA-N Cc1c(CCCO)nc(-c(cc2)ccc2Br)[o]1 Chemical compound Cc1c(CCCO)nc(-c(cc2)ccc2Br)[o]1 ZJTLOCWXAJZYPJ-UHFFFAOYSA-N 0.000 description 1
- ANGHUYMRQZFOTA-UHFFFAOYSA-N Cc1c(CCN2CCCC2)nc(-c(cc2)ccc2-c2cc(OC)cnc2)[o]1 Chemical compound Cc1c(CCN2CCCC2)nc(-c(cc2)ccc2-c2cc(OC)cnc2)[o]1 ANGHUYMRQZFOTA-UHFFFAOYSA-N 0.000 description 1
- COTJCXDLLSTAGF-UHFFFAOYSA-N Cc1c(CCN2CCCC2)nc(-c(cc2)ccc2-c2ccc(C#N)[s]2)[o]1 Chemical compound Cc1c(CCN2CCCC2)nc(-c(cc2)ccc2-c2ccc(C#N)[s]2)[o]1 COTJCXDLLSTAGF-UHFFFAOYSA-N 0.000 description 1
- RFXKJMIQHVEWPI-UHFFFAOYSA-N Cc1c(CCO)nc(-c(cc2)ccc2OCc2ccccn2)[o]1 Chemical compound Cc1c(CCO)nc(-c(cc2)ccc2OCc2ccccn2)[o]1 RFXKJMIQHVEWPI-UHFFFAOYSA-N 0.000 description 1
- DBZDCMYNCYHTKL-UHFFFAOYSA-N Cc1c(CCO)nc(C2C=CC(c(cc3)ccc3S(C)(=O)=O)=CC2)[o]1 Chemical compound Cc1c(CCO)nc(C2C=CC(c(cc3)ccc3S(C)(=O)=O)=CC2)[o]1 DBZDCMYNCYHTKL-UHFFFAOYSA-N 0.000 description 1
- WMCKMBIRRGZGLE-YFKPBYRVSA-N FC[C@H]1NCCC1 Chemical compound FC[C@H]1NCCC1 WMCKMBIRRGZGLE-YFKPBYRVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59119104P | 2004-07-26 | 2004-07-26 | |
| US60/591,191 | 2004-07-26 | ||
| PCT/US2005/024883 WO2006019833A1 (en) | 2004-07-26 | 2005-07-14 | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1989115A CN1989115A (zh) | 2007-06-27 |
| CN1989115B true CN1989115B (zh) | 2012-03-21 |
Family
ID=35134220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200580024874XA Expired - Fee Related CN1989115B (zh) | 2004-07-26 | 2005-07-14 | 作为组胺h3受体药物的噁唑衍生物及其制备和制药用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7666871B2 (OSRAM) |
| EP (1) | EP1786790B1 (OSRAM) |
| JP (1) | JP4982367B2 (OSRAM) |
| CN (1) | CN1989115B (OSRAM) |
| AT (1) | ATE432926T1 (OSRAM) |
| AU (1) | AU2005275183B2 (OSRAM) |
| BR (1) | BRPI0513777A (OSRAM) |
| CA (1) | CA2575081C (OSRAM) |
| CY (1) | CY1109493T1 (OSRAM) |
| DE (1) | DE602005014786D1 (OSRAM) |
| DK (1) | DK1786790T3 (OSRAM) |
| ES (1) | ES2325865T3 (OSRAM) |
| MX (1) | MX2007001029A (OSRAM) |
| PL (1) | PL1786790T3 (OSRAM) |
| PT (1) | PT1786790E (OSRAM) |
| SI (1) | SI1786790T1 (OSRAM) |
| WO (1) | WO2006019833A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008301B2 (en) * | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| EP1848428A4 (en) | 2005-02-18 | 2012-04-18 | Neurogen Corp | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGS |
| EP1866293A1 (en) * | 2005-03-31 | 2007-12-19 | UCB Pharma, S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
| US8637559B2 (en) | 2005-11-15 | 2014-01-28 | Otsuka Pharmaceutical Co., Ltd. | Oxazole compound and pharmaceutical composition |
| CA2645731A1 (en) | 2006-03-15 | 2007-09-27 | Wyeth | N-substituted-azacyclylamines as histamine-3 antagonists |
| CA2649913A1 (en) | 2006-05-19 | 2007-11-29 | Wyeth | N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists |
| BRPI0711655A2 (pt) * | 2006-05-19 | 2011-11-29 | Basf Se | composto, processo para preparar compostos, composição, processo para preparar composições, proceeso para combater vegetação indesejada, e, uso do composto |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20081152A1 (es) | 2006-10-06 | 2008-08-10 | Wyeth Corp | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 |
| JP2010533725A (ja) | 2007-07-16 | 2010-10-28 | ワイス・エルエルシー | ヒスタミン‐３（ｈ３）受容体としてのアミノアルキルアゾール化合物 |
| WO2009126782A1 (en) * | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
| US8383829B2 (en) * | 2008-04-15 | 2013-02-26 | Konica Minolta Holdings, Inc. | Electrochromic compound, electrode, and display element |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| SG186275A1 (en) | 2010-07-06 | 2013-01-30 | Astrazeneca Ab | Therapeutic agents 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| SG11201505631PA (en) | 2013-01-23 | 2015-08-28 | Astrazeneca Ab | Chemical compounds |
| WO2016097071A1 (en) * | 2014-12-18 | 2016-06-23 | F. Hoffmann-La Roche Ag | Estrogen receptor modulators and uses thereof |
| PE20180506A1 (es) | 2015-06-03 | 2018-03-09 | Bristol Myers Squibb Co | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| PT3319959T (pt) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Inibidores hetero-halo de histona desacetilase |
| MX394242B (es) | 2017-01-11 | 2025-03-24 | Rodin Therapeutics Inc | Inhibidores biciclicos de histona desacetilasa |
| MX2020001484A (es) | 2017-08-07 | 2020-08-20 | Rodin Therapeutics Inc | Inhibidores bicíclicos de la histona desacetilasa. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000064884A1 (en) * | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3819037A1 (de) * | 1988-06-04 | 1989-12-14 | Hoechst Ag | 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden |
| AU674613B2 (en) * | 1993-09-28 | 1997-01-02 | Otsuka Pharmaceutical Co., Ltd. | Quinoxaline derivative as antidiabetic agent |
| CA2441080A1 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| IL162834A0 (en) | 2002-02-01 | 2005-11-20 | Novo Nordisk As | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes |
| US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| US7259262B2 (en) * | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
-
2005
- 2005-07-14 PL PL05773290T patent/PL1786790T3/pl unknown
- 2005-07-14 MX MX2007001029A patent/MX2007001029A/es active IP Right Grant
- 2005-07-14 JP JP2007523605A patent/JP4982367B2/ja not_active Expired - Fee Related
- 2005-07-14 BR BRPI0513777-2A patent/BRPI0513777A/pt not_active IP Right Cessation
- 2005-07-14 EP EP05773290A patent/EP1786790B1/en not_active Expired - Lifetime
- 2005-07-14 SI SI200530741T patent/SI1786790T1/sl unknown
- 2005-07-14 AT AT05773290T patent/ATE432926T1/de active
- 2005-07-14 DK DK05773290T patent/DK1786790T3/da active
- 2005-07-14 US US11/572,283 patent/US7666871B2/en not_active Expired - Fee Related
- 2005-07-14 CN CN200580024874XA patent/CN1989115B/zh not_active Expired - Fee Related
- 2005-07-14 DE DE602005014786T patent/DE602005014786D1/de not_active Expired - Lifetime
- 2005-07-14 CA CA2575081A patent/CA2575081C/en not_active Expired - Fee Related
- 2005-07-14 WO PCT/US2005/024883 patent/WO2006019833A1/en not_active Ceased
- 2005-07-14 ES ES05773290T patent/ES2325865T3/es not_active Expired - Lifetime
- 2005-07-14 PT PT05773290T patent/PT1786790E/pt unknown
- 2005-07-14 AU AU2005275183A patent/AU2005275183B2/en not_active Ceased
-
2009
- 2009-08-06 CY CY20091100831T patent/CY1109493T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000064884A1 (en) * | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2575081A1 (en) | 2006-02-23 |
| US20070197604A1 (en) | 2007-08-23 |
| EP1786790A1 (en) | 2007-05-23 |
| PT1786790E (pt) | 2009-08-18 |
| AU2005275183A1 (en) | 2006-02-23 |
| EP1786790B1 (en) | 2009-06-03 |
| SI1786790T1 (sl) | 2009-10-31 |
| ATE432926T1 (de) | 2009-06-15 |
| CY1109493T1 (el) | 2014-08-13 |
| US7666871B2 (en) | 2010-02-23 |
| PL1786790T3 (pl) | 2009-10-30 |
| AU2005275183B2 (en) | 2011-03-17 |
| DE602005014786D1 (de) | 2009-07-16 |
| MX2007001029A (es) | 2007-04-12 |
| WO2006019833A1 (en) | 2006-02-23 |
| DK1786790T3 (da) | 2009-07-20 |
| CA2575081C (en) | 2013-05-07 |
| BRPI0513777A (pt) | 2008-05-13 |
| JP2008507579A (ja) | 2008-03-13 |
| JP4982367B2 (ja) | 2012-07-25 |
| ES2325865T3 (es) | 2009-09-22 |
| CN1989115A (zh) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1989115B (zh) | 作为组胺h3受体药物的噁唑衍生物及其制备和制药用途 | |
| AU2005277518B2 (en) | Histamine H3 receptor agents, preparation and therapeutic uses | |
| CN101142217B (zh) | 咪唑并哒嗪化合物 | |
| CN101528717B (zh) | 噻唑和*唑-取代的芳基酰胺类化合物 | |
| CN1960969B (zh) | 组胺h3受体药物、其制备方法及治疗用途 | |
| CN111138301A (zh) | 联苯类化合物、其中间体、制备方法、药物组合物及应用 | |
| CN101903348B (zh) | 吡唑取代的芳基酰胺 | |
| CN102300857A (zh) | N-{[(1r,4s,6r)-3-(2-吡啶基羰基)-3-氮杂双环[4.1.0]庚-4-基]甲基}-2-杂芳基胺衍生物及其用途 | |
| CN102803252A (zh) | 用于治疗神经退化性疾病的吲哚酰胺衍生物及其相关化合物 | |
| WO2007126043A1 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
| JP2013512910A (ja) | ロイコトリエン産生のベンゾイミダゾール阻害薬 | |
| CN104024250A (zh) | 作为痕量胺相关受体(taar)的杂环衍生物 | |
| CN117794898A (zh) | 3-吡咯基磺酰胺化合物作为gpr17拮抗剂 | |
| KR20250103814A (ko) | 용질 담체 계열 6a 구성원 19(slc6a19)의 억제제 및 이의 사용 방법 | |
| CN111356695B (zh) | 新的三环化合物 | |
| CN103261193A (zh) | 抑制白三烯生成的*二唑抑制剂 | |
| WO2006049232A1 (ja) | チアゾール環を含むカルボン酸誘導体およびその医薬用途 | |
| WO2023016530A1 (zh) | 一类3,4-二氢-2H-苯并[b][1,4]噁嗪类化合物及其制备方法 | |
| CN118974013A (zh) | 吡咯烷化合物 | |
| CA2720631C (en) | 3-indazolyl-4-pyridylisothiazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120321 Termination date: 20180714 |